Moderate Evidence
Research Overview
Retinalamin Research for Retinal Dystrophy
An evidence-based overview of research examining Retinalamin in the context of retinal dystrophy. This page synthesizes findings from peer-reviewed literature.
Research Summary
Primary indication in Russian registration is hereditary and acquired retinal dystrophies. Clinical reports suggest functional improvement and disease stabilization in some patients. Evidence quality is low by Western standards; controlled trials are lacking.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Retinal Dystrophy
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Retinalamin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.